Pfizer’s valuation story turns to pipeline progress, oncology pressure, earnings strength, and healthcare execution after a ...

Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury. The company said the injury went away after the person ...

Pfizer returns to market focus after a finance leadership transition, prompting fresh discussion around valuation, pipeline ...

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Yet another experimental drug heavily touted by Pfizer Inc. has foundered in advanced testing, raising worries about productivity ...

Pfizer said Friday it is halting the testing of a twice-daily obesity drug, citing side effects. The company said in a press release it will now focus its future efforts for the drug, danuglipron, on ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

A pill to treat obesity caused liver injury in a clinical trial Pfizer said it will stop developing the drug, called danuglipron, as a result Other alternatives to injectable obesity drugs are in ...